

EUROPEAN PHARMACOPOEIA COMMISSION

CV/lke

Working document, with no legally binding status, intended exclusively for the addressees and their associates, under the responsibility of the addressees (listed opposite). Level 4

PA/PH/SG (11) 86

# BILINGUE

GROUP COM

Strasbourg, December 2011

(EUROPEAN PHARMACOPOEIA COMMISSION / COMMISSION EUROPEENNE DE PHARMACOPEE)

## Summary of Decisions taken at the 141st Session

Résumé des Décisions prises lors de la 141e Session

Strasbourg, 22-23 November 2011

### Distribution

#### For action:

COM European Pharmacopoeia Commission

#### For information :

ANP National Pharmacopoeia Authorities  
PRES Praesidium

**EUROPEAN PHARMACOPOEIA COMMISSION  
COMMISSION EUROPEENNE DE PHARMACOPÉE**

**Summary of Decisions of the 141<sup>st</sup> Session  
22-23 November 2011**

**Résumé des décisions de la 141<sup>e</sup> Session  
22-23 novembre 2011**

**Deadline for confirmation / Date de confirmation : 2 January 2012**

<b>Item</b>	<b>I. ADOPTED TEXTS</b>	<b>Subject to Confirmation</b>
	<b>I.1 Monographs and chapters/Monographies et chapitres</b>	
	<b>I.1.1 Minor revisions / Révisions mineures</b>	
15.3.1	Amoxicillin trihydrate / Amoxicilline trihydratée (260)	
24.3.1	Artichoke leaf / Artichaut (feuille d') (1866)	
21.3.1	Benzyl alcohol/Benzylique (alcool) (256)	
73.3.1	Calcifediol / Calcifédiol (1295)	
73.3.2	Calcitriol / Calcitriol (0883)	
52.3.1	Calcium gluconate / Calcium (gluconate de) (172)	
52.3.2	Calcium gluconate for injection / Calcium (gluconate de) pour solution injectable (979)	
52.3.4	Calcium hydrogen phosphate dihydrate / Calcium (hydrogénophosphate de) dihydraté (116)	
52.3.3	Calcium hydrogen phosphate, anhydrous / Calcium (hydrogénophosphate de) anhydre (981)	
15.3.2	Cefprozil monohydrate / Cefprozil monohydraté (2342)	
15.3.3	Ceftazidime pentahydrate / Ceftazidime pentahydratée (1405)	
15.3.4	Ceftazidime pentahydrate with sodium carbonate for injection / Ceftazidime pentahydratée avec du carbonate de sodium pour préparations injectables (2344)	
73.3.3	Cholecalciferol / Cholécalfiferol (0072)	
18.3.2	Fentanyl (1210)	
18.3.3	Fentanyl citrate/Fentanyl (citrate de) (1103)	
52.3.5	Ferrous gluconate / Gluconate ferreux (493)	
23.3.1	Fourstamen stephania root / Stéphania (racine de) (2478)	
19.3.1	Gabapentin / Gabapentine (2173)	
21.3.6	Glucosamine hydrochloride / Glucosamine (chlorhydrate de) (2446)	
21.3.5	Glucosamine sulfate sodium chloride / Glucosamine (sulfate de) - chlorure de sodium (2447)	
18.3.1	Hydrochlorothiazide (394)	
52.3.6	Hydrogen peroxide solution (3 per cent) / Hydrogène (peroxyde d'), solution de, à 3 pour cent (395)	

	<b>I.1.1 Minor revisions / Révisions mineures</b>	
52.3.7	Hydrogen peroxide solution (30 per cent) / Hydrogène (peroxyde d'), solution de, à 30 pour cent (396)	
24.3.2	Indian frankincense / Encens indien (2310)	
15.3.5	Ivermectin / Ivermectine (1336)	
21.3.2	Levothyroxine sodium / Lévothyroxine sodique (401)	
52.3.8	Magnesium peroxide / Magnésium (peroxyde de) (1540)	
25.3.2	Methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent / Copolymère d'acide méthacrylique et d'acrylate d'éthyle (1:1) (dispersion de) à (1129)	
17.3.1	Metronidazole benzoate / Métronidazole (benzoate de) (934)	
25.3.1	Polyacrylate dispersion 30 per cent / Polyacrylate (dispersion de) à 30 pour cent (733)	
21.3.4	Pyridostigmine bromide / Pyridostigmine (bromure de) (1255)	
21.3.3	Rutoside trihydrate / Rutoside trihydraté (1795)	
52.3.9	Sodium perborate, hydrated / Sodium (perborate de) hydraté (1997)	
20.3.1	Sodium picosulfate / Sodium (picosulfate de) (1031)	
37.3.1	Sulfur dioxide / Dioxyde de soufre (2.5.29.)	
22.3.1	Tablets / Comprimés (478)	
73.3.4	Thiamine nitrate / Thiamine (nitrate de)	
27.3.1	Yellow fever vaccine (live) Vaccin vivant de la fièvre jaune (537)	
	<b>I.1.2 Revisions / Révisions</b>	
20.2.1	Acesulfame potassium / Acésulfame potassique (1282)	
24.2.1	Angelica root / Angélique (racine d') (1857)	
25.2.5	Basic butylated methacrylate copolymer / Copolymère basique de méthacrylate de butyle (1975)	
66.2.1	Bulk density and tapped density of powders / Masse volumique vrac et masse volumique après tassement (2.9.34.)	
25.2.1	Castor oil, refined / Ricin (huile de) raffinée (2367)	
25.2.2	Castor oil, virgin / Ricin (huile de) vierge (51)	
15.2.1	Cefoxitin sodium/Céfoxitine sodique (990)	
68.2.1	Code of Practice for the work of the European Pharmacopoeia / Règles de déontologie relatives aux travaux de la Pharmacopée Européenne	
15.2.3	Colistin sulfate/Colistine (sulfate de) (320)	
19.2.1	Doxylamine hydrogen succinate / Doxylamine (hydrogénosuccinate de) (1589)	
23.2.3	Elder flower / Sureau (fleur de) (1217)	
24.2.2	Fumitory / Fumeterre (1869)	

	<b>I.1.2 Revisions / Révisions</b>	
18.2.1	Furosemide / Furosémide (391)	
11.3	General notices / Prescriptions générales (1.)	
17.2.1	Glibenclamide (718)	
25.2.4	Glycerol distearate / Glycérol (distéarate de) (1428)	
24.2.3	Goldenrod, European / Solidage verge d'or (1893)	
13.2.1	Goserelin / Goséréline (1636)	
68.2.3	Guide for Work of the European Pharmacopoeia / Guide des Travaux de la Pharmacopée Européenne	
27.2.3	Haemophilus type b conjugate vaccine / Vaccin conjugué de l'haemophilus type b (1219)	
18.2.3	Haloperidol / Halopéridol (616)	
24.2.4	Herbal teas / Plantes pour tisanes (1435)	
14.2.2	Human albumin solution / Albumine humaine (solution d') (255)	
14.2.1	Human normal immunoglobulin / Immunoglobuline humaine normale (338)	
25.2.3	Identification of fatty oils by thin-layer chromatography / Identification des huiles grasses par chromatographie sur couche mince (20302)	
18.2.2	Iohexol (1114)	
24.2.5	Ivy leaf / Lierre (feuille de) (2148)	
24.2.6	Lovage root / Livèche (racine de) (1233)	
25.2.6	Macrogol poly(vinyl alcohol) grafted copolymer / Copolymère greffé de macrogol et de poly(alcool vinylique) (2523)	
29.2.1	Materials used for the manufacture of containers (3.1.) / Matériaux utilisés dans la fabrication des récipients (30100)	
18.2.4	Medroxyprogesterone acetate / Médroxyprogestérone (acétate de) (673)	
18.2.5	Megestrol acetate / Mégestrol (acétate de) (1593)	
27.2.4	Meningococcal group C conjugate vaccine / Vaccin conjugué méningococcique groupe C (2112)	
19.2.2	Methylphenidate hydrochloride / Méthylphénidate (chlorhydrate de) (2235)	
23.2.1	Motherwort / Agripaume (1833)	
21.2.1	Oxymetazoline hydrochloride / Oxymétazoline (chlorhydrate d') (943)	
27.2.2	Pneumococcal polysaccharide conjugate vaccine (adsorbed) / Vaccin pneumococcique polysaccharidique conjugué adsorbé (2150)	
50.2.1	Procedure No. 5 for the Elaboration of Monographs / Procédure n° 5 d'élaboration des monographies	
17.2.1	Pyrazinamide (859)	

	<b>I.1.2 Revisions / Révisions</b>	
26.2.1	Radiopharmaceutical preparations / Préparations radio-pharmaceutiques (125)	
24.2.7	Roselle / Karadé (1623)	
23.2.2	Rosemary leaf / Romarin (1560)	
68.2.2	Rules of Procedure of the European Pharmacopoeia Commission / Règlement Intérieur de la Commission Européenne de Pharmacopée	
24.2.8	St. John's wort dry extract, quantified / Millepertuis (extrait sec quantifié de) (1874)	
37.2.2	Starch, hydroxypropyl / Amidon hydroxypropylé (2165)	
15.2.2	Sulfadimidine (295)	
27.2.1	Vaccines for human use Vaccins pour usage humain (153)	
11.2	Water: semi-micro determination / Semi-microdosage de l'eau (2.5.12.)	
24.2.9	Willow bark / Saule (écorce de) (1583)	
	<b>I.1.3 New texts for adoption / Nouveaux textes pour adoption</b>	
50.1.1	Anarmita cocculus/Cocculus indicus for homoeopathic preparations (2486)	
66.1.1	Characterisation of crystalline solids by microcalorimetry and solution calorimetry / Caractérisation des solides cristallins par microcalorimétrie et calorimétrie en solution (20261)	
72.1.1	Coix seed / Larme de Job (graine de) (2454)	
23.1.4	Common selfheal fruit spike / Brunelle commune (épi fructifère de) (2439)	
26.1.1	Gallium-DOTA-(Tyr3)-octreotide(68Ga) injection / Gallium-DOTA-(Tyr3)-octréotide(68Ga) (solution injectable de) (2482)	
23.1.1	Ginseng dry extract / Ginseng (extrait sec de) (2356)	
24.1.1	Instant herbal teas / Préparations instantanées pour tisanes (2620)	
63.1.1	Insulin glargine / Insuline glargine (2571)	
23.1.3	Long pepper / Poivre long (2453)	
30.1.4	Lopinavir / Lopinavir (2615)	
72.1.2	Magnolia officinalis bark / Magnolia officinalis (écorce de) (2567)	
30.1.3	Nevirapine hemihydrate / Névirapine hémihydratée (2479)	
72.1.3	Orientvine stem / Sinoménum (tige de) (2450)	
23.1.2	Pepper / Poivre (2477)	
65.1.1	Pharmaceutical preparations / Préparations pharmaceutiques (2619) <sup>1</sup>	DE, CZ
30.1.2	Pioglitazone Hydrochloride / Pioglitazone (chlorhydrate de) (2601)	

<sup>1</sup> New version of the monograph submitted to all delegations: see letter sent by the Secretariat on 2/12/11

	<b>I.1.3 New texts for adoption / Nouveaux textes pour adoption</b>	
19.1.1	Quinapril hydrochloride / Quinapril (chlorhydrate de) (1763)	
30.1.5	Rivastigmine / Rivastigmine (2629)	
30.1.1	Sildenafil citrate / Sildénafil (citrate de) (2270)	
11.1	Voltametric titration / Titrage voltamétrique (2.2.65.)	
	<b><i>I-2 CRS/BRP SCR/PBR</i></b>	
	<b>New substances / Nouvelles substances</b>	
	2- Methylpyrazine CRS 1	
	Bicalutamide CRS 1	
	Bicalutamide for system suitability CRS 1	
	Cefprozil CRS 1	
	Cefprozil for peak identification CRS 1	
	Cefprozil Impurity A CRS 1	
	Cefprozil Impurity mixture CRS 1	
	Chlortetracycline for system suitability CRS 1	
	Dexamethasone sodium phosphate for peak identification CRS 1	
	Difloxacin hydrochloride CRS 1	
	Difloxacin Impurity G CRS 1	
	Diphenoxylate for system suitability CRS 1	
	Diphenoxylate hydrochloride CRS 1	
	Fulvestrant CRS 1	
	Fulvestrant CRS 1	
	Fulvestrant for system suitability CRS 1	
	Glucosamine for system suitability CRS 1	
	Glucosamine hydrochloride CRS 1	
	Glucosamine sulfate sodium chloride CRS 1	
	Glycerol formal CRS 1	
	Homatropine methylbromide for system suitability CRS 1	
	Hydrocortisone acetate for peak identification CRS 1	
	Levothyroxine for peak identification CRS 1	
	Lincomycin for system suitability CRS 1	
	Melphalan for system suitability CRS 1	
	Melphalan reference spectrum	
	Minoxidil for system suitability CRS 1	
	Nateglinide CRS 1	
	Nateglinide Impurity A CRS 1	
	Nateglinide Impurity B CRS 1	
	Nateglinide Impurity C CRS 1	
	Nicotine ditartrate dihydrate CRS 1	

	<b>New substances / Nouvelles substances</b>	
	Nitrendipine for peak identification CRS 1	
	Olanzapine CRS 1	
	Piretanide for system suitability CRS 1	
	Prilocaine Impurity B CRS 1	
	Sodium iodohippurate CRS 1	
	Tadalafil CRS 1	
	Triamcinolone acetonide for system suitability CRS 1	
	Vigabatrin CRS 1	
	Vigabatrin impurity A CRS 1	
	Vigabatrin impurity D CRS 1	
	Vigabatrin impurity E CRS 1	
	Vigabatrin impurity B CRS 1	
	Voriconazole CRS 1	
	Voriconazole Impurity B CRS 1	
	Voriconazole Impurity D CRS 1	
	Voriconazole Impurity E CRS 1	
77.1	<b>Replacement batches / Lots de remplacement</b>	
	4-Aminobenzoic acid CRS 2	
	Acetylcysteine CRS 3	
	Adrenaline impurity mixture CRS 2	
	Amisulpride CRS 2	
	Atracurium besilate CRS 2	
	Azathioprine impurity G CRS 2	
	Azithromycin for system suitability CRS 5	
	Betahistidine dihydrochloride CRS 2	
	Bisoprolol for system suitability CRS 2	
	Buflomedil Impurity B CRS 3	
	Calibration of the Human Immunoglobulin BRP for ACA and HPLC Batch 1 and Human Immunoglobulin BRP for Fc function and HPLC Batch 1 and Batch 2.	
	Clarithromycin CRS 3	
	Crotamiton Impurity A CRS 3	
	Dehydrohexetidine CRS 2	
	Deoxyminoxidil CRS 5	
	Diclofenac Impurity A CRS 7	
	Dicycloverine hydrochloride CRS 2	
	Doxorubicin hydrochloride CRS 6	
	Ergosterol CRS 5	

	<b>Replacement batches / Lots de remplacement</b>	
	Ethinylestradiol CRS 4	
	Flucloxacillin sodium CRS 7	
	Framycetin sulfate CRS 5	
	Ginkgolic acids CRS 2	
	Gliclazide impurity F CRS 4	
	Hydrochlorothiazide CRS 6	
	Ifosfamide Impurity A CRS 3	
	Insulin aspart CRS 2	
	Ivermectin CRS 2	
	Ivermectin CRS 2	
	Kanamycin B sulfate CRS 3	
	Medroxyprogesterone acetate for performance test CRS 3	
	Methylnitrosoindoline CRS 3	
	Moxidectin CRS 2	
	Neohesperidin-dihydrochalcone Impurity B CRS 2	
	Palmitic Acid CRS 4	
	Plastic additive 08 CRS 3	
	Plastic additive 15 CRS 2	
	Raniditine Impurity J CRS 5	
	Salmeterol xinafoate CRS 2	
	Sertraline for peak identification CRS 2	
	Sertraline HCl for system suitability CRS 2	
	Sisomicin sulfate CRS 2	
	Sodium stearyl maleate CRS 2	
	Sumatriptan impurity mixture CRS 7	
	Testosterone propionate CRS 2	
	Tobramycin CRS 4	
	Tramadol Impurity A CRS 4	
	Zopiclone CRS 2	
	<b>II. ITEMS DEFERRED – SCHEDULED FOR NEXT SESSION/ SUJETS REPORTES – A INSCRIRE A LA PROCHAINE SESSION</b>	
<b>Item</b>	<b>III. WORK PROGRAMME/PROGRAMME DE TRAVAIL</b>	
	<b>III.1 Requests for revision / Demandes de révision</b>	
18.4.1	Alfuzosin hydrochloride / Alfuzosine (chlorhydrate d') (1287) -> Group 10B	



	<b>III.1 Requests for revision / Demandes de révision</b>	
14.4.1	Anti-A and anti-B haemagglutinins / Titre en hémagglutinines anti-A et anti-B (2.6.20.) -> Group 6B	
24.4.1	Artichoke leaf / Artichaut (feuille d') (1866) -> Group 13B	
23.4.2	Bitter-fennel fruit oil / Fenouil amer (fruit de), huile essentielle de (1826) -> Group 13A	
23.4.2	Bitter-fennel herb oil / Fenouil amer (parties aériennes de), huile essentielle des (2380) -> Group 13A	
24.4.2	Boldo leaf dry extract / Boldo (feuille de), extrait sec de (1816) -> Group 13B	
18.4.2	Bromhexine hydrochloride / Bromhexine (chlorhydrate de) (706) -> Group 10B	
14.6	Conversion of the texts to the format from the Technical guide on Human plasma derived products published in 2011 -> Group 6B to continue	
23.4.1	Coriander / Coriandre (1304) -> Group 13A	
18.4.3	Dexamethasone acetate / Dexaméthasone (acétate de) (548) -> Group 10B	
37.4.1	Dextranomer / Dextranomère (2238) -> CRB WP	
19.4.1	Esomeprazole magnesium trihydrate / Ésoméprazole magnésique trihydraté (2372) -> Group 10C	
23.4.2	Fennel, bitter / Fenouil amer (fruit de) (824) -> Group 13A	
23.4.2	Fennel, sweet / Fenouil doux (fruit de) (825) -> Group 13A	
18.4.4	Fentanyl (1210) -> Group 10B	
18.4.5	Fentanyl citrate/Fentanyl (citrate de) (1103) -> Group 10B	
6.8.2.2	Filgrastim concentrated solution (2206) -> Group 6	
24.4.3	Fumitory / Fumeterre (1869) -> Group 13B	
18.4.6	Furosemide / Furosémide (391) -> Group 10B	
45	Glass containers for pharmaceutical use / Récipients de verre pour usage pharmaceutique (3.2.1) -> GLS WP	
14.4.3	Human normal immunoglobulin Immunoglobuline humaine normale (338) -> Group 6B	
14.4.2	Human plasma (pooled and treated for virus inactivation) / Plasma humain (mélange de) traité pour viro-inactivation (1646) -> Group 6B	
63.1.1	Insulin glargine / Insuline glargine (2571) -> Group 6	
24.4.4	Ispaghula seed / Ispaghul (graine d') (1333) -> Group 13B	
17.4.1	Molsidomine (1701) -> Group 10A	
50.4.1	Mother tinctures for homoeopathic preparations/Teintures mères pour préparations homéopathiques (2029) -> HOM WP	
30.4.2	Moxifloxacin hydrochloride / Moxifloxacine (chlorhydrate de) (2254) -> Group 10A	

	<b>III.1 Requests for revision / Demandes de révision</b>	
25.4.2	Omega-3-acid ethyl esters 90 / Oméga-3 (esters éthyliques 90 d'acides) (1250) -> Group 13H	
21.4.1	Oxitropium bromide / Oxitropium (bromure d') (2170) -> Group 11	
28.4.1	Plastic containers and closures for pharmaceutical use / Récipients et fermetures en matière plastique pour usage pharmaceutique (30202) -> Group 16	
28.4.1	Rabies vaccine (inactivated) for veterinary use / Vaccin rabique inactivé pour usage vétérinaire (451) -> Group 15V	
64.4.1	Raman spectrometry / Spectrométrie raman (20248) -> PAT WP	
24.4.4	Rhatany root / Ratanhia (racine de) (289) -> Group 13B	
24.4.4	Rhatany tincture / Ratanhia (teinture de) (1888) -> Group 13B	
30.1.1	Sildenafil citrate / Sildénafil (citrate de) (2270) -> Group 10B	
25.4.1	Sucrose stearate / Saccharose (stéarate de) (2318) & Sucrose mono-palmitate / Saccharose (monopalmitate de) (2319) -> Group 13H	
24.4.5	Turmeric, Javanese / Temoe lawacq (1441) -> Group 13B	
28.4.2	Vaccines for veterinary use / Vaccins pour usage vétérinaire (62) -> Group 15V	
24.4.6	Valerian dry hydroalcoholic extract / Valériane (extrait hydroalcoolique sec de) (1898) -> Group 13B	
15.4.1	Vancomycin hydrochloride / Vancomycine (chlorhydrate de) (1058) -> Group 7	
74.4.1	Water for injections/Eau pour préparations injectables (0169) -> WAT WP	
23.4.3	Yarrow / Achillée millefeuille (1382) -> Group 13A	
	<b>III.2 Additions to the work programme</b>	
8.2	Aluminium chloride anhydrous	
8.2	Clopidogrel besilate	
8.2	Clopidogrel hydrochloride	
8.2	Diclofenac diethylamine	
6.4	Ferrosoferric phosphate for hom. preps	
8.1	Fluoromethylcholine (18F) injection	
8.1	Formic acid 98%	
8.2	Glutamic acid hydrochloride / Aciglumine	
6.4	Grindelia for hom. preps	
8.1	Human normal immunoglobulin for subcutaneous administration	
8.1	Indium ( <sup>111</sup> In) pentetreotide	
8.1	Liquid sugar	
8.1	Lutetium ( <sup>177</sup> Lu) for radiolabelling	

	<b>III.2 Additions to the work programme</b>	
8.2	Papaverine sulfate	
6.8.2.3	Pegfilgrastim	
6.8.2.3	Peginterferon alfa-2a	
8.1	Propylene glycol monocaprylate	
8.2	Ropivacain hydrochloride anhydrous	
8.2	Scopolamine / Hyoscine methylnitrate	
6.4	Silver fir for hom. preps	
6.8.3	Squalene	
8.1	Sulfobutyl ether betacyclodextrin sodium	
8.1	Sweet-fennel fruit oil	
8.2	Tylosinum phosphatum (substance, no solution)	
8.1	Yttrium ( <sup>90</sup> Y) for radiolabelling	
	<b>III.3 Suppression from the work programme</b>	
19.5.1	Acrivastine (1744)	
8.1	Cypermethrin (2592)	HU
15.5.1	Dihydrostreptomycin sulfate for veterinary use / Dihydrostreptomycine (sulfate de) pour usage vétérinaire (485)	
27.5.2	Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactiv / Vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé) et polio (1934)	
27.5.1	Japanese encephalitis vaccine (inactivated) / Vaccin inactivé de l'encéphalite japonaise (1930)	
27.5.3	Vaccines for human use / Vaccins pour usage humain (153)	
	<b>III.4 Suppression from the Ph. Eur.</b>	
13.5.1	Protamine hydrochloride: Suppression - follow-up to the 140th Session	
<b>Agenda Item No.</b>	<b>IV. PROCEDURES AND QUESTIONS OF PRINCIPLE/ PROCEDURES ET QUESTIONS DE PRINCIPE</b>	
6.8.1.2	Terms of Reference for the RMP Working Party Adopted -> Secretariat to invite delegations to propose nominations	
6.8.2.1	Terms of Reference for the HCP Working Party Adopted -> Secretariat to invite delegations to propose nominations	
6.8.2.2	Finished product monographs for biological: Agreement to start a pilot phase with elaboration of a monograph on Filgrastim concentrated solution (2206)	

7.2	Application for Observer Status from Singapore -> Awaiting reply from EU. 6 Non-EU countries in favour	
45	Glass delamination GLS WP to continue studying this question	
	<b>V. DATES OF FUTURE SESSIONS/DATE DE LA PROCHAINE SESSION DE LA COMMISSION</b>	
	- 3-4 April 2012 - 19-20 June 2012 - 27-28 November 2012	

ANNEX I  
**141<sup>st</sup> Session Nominations**  
**November 2011 SESSION**

**ITEM 7.1**

**GROUPS OF EXPERTS**

Group 6

Sweden	Dr Ezra Mulugeta (replacing Dr Arvidsson)
The Netherlands	Dr Edwin Kellenbach (replacing Dr Overbeeke)

Group 12

Hungary	Dr Beata Szabady (replacing Dr Tuske)
Denmark	Dr Poul Bertelsen (replacing Mrs B Møllgaard)

Group 13B

Turkey	Prof. Dr. L Omur Demirezer (replacing Prof Can Baser)
--------	---

Group 13H

Turkey	Prof. Dr. Ilkay Erdogan Orhan
--------	-------------------------------

Group 15V

Turkey	Dr Alp Aykac (replacing Dr Senem Haciomeroglu)
Slovak Republic	Mrs R. Kovacova
Finland	Dr K. Lehmann (Specialist Immunological vet. Products, Infectious animal diseases)

Group P4

Serbia	Dr M Malesevic (replacing Mrs Maskovic)
--------	---

**WORKING PARTIES**

CND (Conductivity)

Germany	Dr Klaus Reithmayer
---------	---------------------

GLS (Glass Containers)

Germany	<b><u>Chair:</u></b> Dr Joerg Zuercher
Switzerland	Dr Juergen Thuerk

## HMM (Homoeopathic Manufacturing Methods)

Germany	Mrs Ute Norwig (replacing (Dr Hippe)
---------	--------------------------------------

## HOM (Homoeopathic Raw Materials and Stocks)

Austria	Dr Robert Muentz (replacing Dr Martin Peithner)
---------	---

## MMM (Modern Microbiological Methods)

Germany	Mr T Montag-Lessing
---------	---------------------

## NIR (Near infrared spectrometry)

Germany	Prof. Dr. Heinz Wilhelm Siesler
---------	---------------------------------

Spain	Dr Marcelo Blanco Romia
-------	-------------------------

## PAT (Process Analytical Technology)

Austria	Dr Walter Schuh (replacing Dr Max Andre)
---------	--

## PHP (Pharmaceutical Preparations)

Austria	Dr Erich Leitner
---------	------------------

## ST (Standard Terms)

Slovenia	Ms Tanja Tekavcic Glover
----------	--------------------------

## TCM (Traditional Chinese Medicines)

Turkey	Prof. Dr. Sebnem Harput (replacing Prof. Can Baser)
--------	---

## WAT (Water for Pharmaceutical Use)

United Kingdom	Mr Andrew Hopkins
----------------	-------------------

Switzerland	Dr Philippe Blanco
-------------	--------------------

France	Mr B Ramond
--------	-------------

**CHAIR OF THE MYCOPLASMA WORKING PARTY (MYC)**

Germany	Dr Sven Deutschmann
---------	---------------------

**NEWLY APPOINTED WORKING PARTIES**Extracts (EXT)

Austria	Dr Reinhard Laenger
Germany	Dr Frank Waimer Dr B Klier Mr K Reh
United Kindom	<b><u>Chair:</u></b> Dr Keith Helliwell
Switzerland	Dr Bilkis Heneka Prof. Beat Meier
Spain	Mrs Gloria Garcia Lorente Dr Pilar Pais Prof. Dr Salvador Cañigüeral
France	Mr Didier Guedon
Belgium	Dr Heidi Neef

Non-Biological Complexes (NBC)

Switzerland	Dr Erik Philipp
Spain	Dr Maria Rosa Virto Garcia
Denmark	Dr Kim Nordfeld
Italy	Dr Lino Liverani